Treatment in hormone-sensitive metastatic prostate cancer: factors to consider when personalizing therapy.

The addition of the androgen-signaling inhibitors (ASI) apalutamide, enzalutamide and abiraterone acetate or docetaxel to standard androgen deprivation therapy (ADT) has been demonstrated to improve overall survival in men with hormone-sensitive metastatic prostate cancer (HSMPC). Areas covered: The majority of men presenting with metastatic prostate cancer will now benefit from the addition of either a novel ASI or docetaxel to standard ADT. In the absence of comparative studies of these agents, clinicians are left with assessing the individual studies and attempting to individualize therapy.Expert opinion: ADT with either docetaxel or androgen-signaling inhibitors (ASI) have changed the treatment landscape of HSMPC with clinically meaningful improvement in overall survival compared to ADT alone. Among the factors to consider in the selection of the optimal agent include the volume of disease, performance status and comorbidities, toxicity profile cost and drug availability, and further resistance or sequencing options.

Expert review of anticancer therapy. 2020 May 14 [Epub ahead of print]

Jeanny B Aragon-Ching, Robert Dreicer

GU Medical Oncology, Inova Schar Cancer Institute, Fairfax, VA, USA., University of Virginia Cancer Center, Charlottesville, VA, USA.